Deacetylasperulosidic Acid

Synonyms: 去乙酰车叶草苷酸
Deacetylasperulosidic Acid 是一种具有口服活性的抗氧化剂,通过增强 SOD 活性发挥明确的体内抗氧化作用并减轻氧化应激损伤,在特应性皮炎模型中能纠正 Th2 偏向的免疫失衡并降低过敏相关因子,在免疫抑制模型中能激活细胞免疫、增强 NK 细胞活性和 IL-2 产生,因此可用于特应性皮炎的研究。
产品编号: MS-I71671 纯度: 99.44% CAS No.: 14259-55-3 分子式: C16H22O11 分子量: 390.34
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

Deacetylasperulosidic Acid 是一种具有口服活性的抗氧化剂,通过增强 SOD 活性发挥明确的体内抗氧化作用并减轻氧化应激损伤,在特应性皮炎模型中能纠正 Th2 偏向的免疫失衡并降低过敏相关因子,在免疫抑制模型中能激活细胞免疫、增强 NK 细胞活性和 IL-2 产生,因此可用于特应性皮炎的研究。

生物实验数据

生物活性 Deacetylasperulosidic Acid is an orally active antioxidant that exerts a well-defined in vivo antioxidant effect and alleviates oxidative stress injury by enhancing SOD activity, corrects Th2-biased immune imbalance and reduces allergy-related factors in atopic dermatitis models, and activates cellular immunity by enhancing NK cell activity and IL-2 production in immunosuppression models, and can therefore be used for research on atopic dermatitis.
IC50 & Target

IL-2

 

体外研究
(In Vitro)

Deacetylasperulosidic Acid 可将 4-硝基喹啉-1-氧化物诱导的遗传毒性降低 98.96%。
Deacetylasperulosidic Acid 可抑制低密度脂蛋白氧化。
Deacetylasperulosidic Acid 可抑制 TNF-α 的释放。
Deacetylasperulosidic Acid 可抑制染色体畸变的诱导。
Deacetylasperulosidic Acid 可通过维持免疫平衡与皮肤屏障功能,在人 HaCaT 角质形成细胞、HMC-1 肥大细胞及 EOL-1 嗜酸性粒细胞中展现抗特应性活性。

体内研究
(In Vivo)

Deacetylasperulosidic Acid (15-60 mg/kg; p.o.; 每日一次共 7 天) 对大鼠具有剂量依赖性的体内抗氧化活性。
Deacetylasperulosidic Acid (30-100 mg/kg; p.o.; 每日一次共 7-14 天) 显著抑制埃利希腹水癌小鼠腹水上清 (EC-sup) 或 Methotrexate (MS-M11188) 引起的耳肿胀减轻,即恢复被抑制的迟发型超敏反应 (DTH)。
Deacetylasperulosidic acid (3-12 mg/kg; p.o.; 每日一次共 4 周) 可通过减轻瘙痒、恢复免疫平衡及修复皮肤屏障功能,以剂量依赖的方式缓解 DNCB 诱导的小鼠特应性皮炎。

Animal Model: Wistar rats (male and female, 180-200 g)
Dosage: 15 mg/kg; 30 mg/kg; 60 mg/kg
Administration: p.o.; daily; 7 days
Result: Caused non-significant reduction in mean serum malondialdehyde (MDA) and 10% increase in mean serum superoxide dismutase (SOD) activity at 15 mg/kg.
Induced significant 19.7% reduction in mean serum MDA and significant 11.3% increase in mean serum SOD activity at 30 mg/kg.
Induced significant 22.6% reduction in mean serum MDA and significant 13.0% increase in mean serum SOD activity at 60 mg/kg.
Did not significantly alter serum glutathione peroxidase (GPx) activity at any tested dose.
Animal Model: ICR (female, 6 weeks old)
Dosage: 30 mg/kg; 100 mg/kg
Administration: p.o.; daily; 7-14 days
Result: Inhibited the reduction of ear swelling by 55%.
Inhibited the reduction of ear swelling by 52%.
Inhibited the reduction of IL-2 production in EC-sup-treated mice.
Increased NK cell cytotoxicity to 12%.
Increased NK cell cytotoxicity to 21%.
Had no effect on splenic lymphocyte subpopulations (CD3+, CD4+, CD8+, B220+, CD49b+ cell percentages).
Animal Model: BALB/c (female, 6 weeks old)
Dosage: 30 mg/kg; 100 mg/kg
Administration: p.o.; daily; 14 days
Result: Resulted in a non-statistically significant increasing trend in IL-2 production and non-statistically significant decreasing trends in IL-4 and IL-10 production.
Had no effect on splenic lymphocyte subpopulations (CD3+, CD4+, CD8+, B220+, CD49b+ cell percentages).
Animal Model: NC/Nga (male, 4 weeks old, DNCB-induced atopic dermatitis)
Dosage: 3 mg/kg; 6 mg/kg; 12 mg/kg
Administration: p.o.; daily; 4 weeks
Result: Reduced dermatitis scores, scratching behavior, and ear thickness in a dose-dependent manner, with 12 mg/kg showing greater efficacy than prednisolone for ear thickness by week 14.
Reduced epidermal thickness and the number of infiltrated mast cells and eosinophils in dorsal skin in a dose-dependent manner; 12 mg/kg achieved epidermal thickness (14.7 μm) and inflammatory cell counts similar to normal mice.
Reduced serum IgE and histamine levels in a dose-dependent manner, with all doses showing greater inhibition than prednisolone.
Reduced serum IgG1 levels and increased serum IgG2a levels in a dose-dependent manner, normalizing the IgG1/IgG2a ratio; 12 mg/kg restored the ratio to near-normal levels.
Reduced serum levels of Th2 (IL-4, IL-10, TSLP), pro-inflammatory (IL-1β, IL-6, TNF-α), and chemokine (TARC, MDC, RANTES) factors, and restored serum levels of Th1 (IL-12, IFN-γ) factors in a dose-dependent manner; 12 mg/kg restored IL-12 and IFN-γ to normal levels.
Reduced splenocyte secretion of Th2 (IL-4, IL-5, IL-10, IL-13, IL-31, IL-33, TSLP), pro-inflammatory (IL-1β, IL-6, TNF-α), Th9/Th17/Th22 (IL-9, IL-17, IL-22), and chemokine (TARC, MDC, RANTES) factors, and restored splenocyte secretion of Th1 (IL-12, IFN-γ) factors in a dose-dependent manner; 12 mg/kg restored IL-12 and IFN-γ to normal levels.
Reduced dorsal skin gene expression of Th2 activation-related factors (CCR4, IL-25, IL-33, TSLP, TARC, MDC, RANTES), Th2 (IL-4, IL-5, IL-10, IL-13, IL-31), pro-inflammatory (IL-1β, IL-6, TNF-α), and Th9/Th17/Th22 (IL-9, IL-17, IL-22) factors, and restored dorsal skin gene expression of Th1 (IL-12, IFN-γ) factors in a dose-dependent manner; 12 mg/kg restored IL-12 and IFN-γ to normal levels.
Increased dorsal skin pro-filaggrin gene expression and skin barrier-related protein (filaggrin, involucrin, loricrin) levels in a dose-dependent manner; 12 mg/kg restored these to levels similar to normal mice, with greater efficacy than prednisolone.
性状 固体
颜色 White to off-white

化学信息

分子量 390.34
分子式 C16H22O11
CAS No. 14259-55-3
别名 去乙酰车叶草苷酸

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.56 mM), Sonication is recommended.
10% DMSO+90% Saline: 10 mg/mL (25.62 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

-20°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (256.19 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

H2O 中的溶解度 : 50 mg/mL (128.09 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O / DMSO1 mM2.5619 mL12.8093 mL25.6187 mL64.0467 mL
5 mM0.5124 mL2.5619 mL5.1237 mL12.8093 mL
10 mM0.2562 mL1.2809 mL2.5619 mL6.4047 mL
15 mM0.1708 mL0.8540 mL1.7079 mL4.2698 mL
20 mM0.1281 mL0.6405 mL1.2809 mL3.2023 mL
25 mM0.1025 mL0.5124 mL1.0247 mL2.5619 mL
30 mM0.0854 mL0.4270 mL0.8540 mL2.1349 mL
40 mM0.0640 mL0.3202 mL0.6405 mL1.6012 mL
50 mM0.0512 mL0.2562 mL0.5124 mL1.2809 mL
60 mM0.0427 mL0.2135 mL0.4270 mL1.0674 mL
80 mM0.0320 mL0.1601 mL0.3202 mL0.8006 mL
100 mM0.0256 mL0.1281 mL0.2562 mL0.6405 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础